Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Debt / NOTE 3.000% 8/1
-
Market price (% of par)
-
98.88%
-
Total 13F principal
-
$143,729,000
-
Principal change
-
-$3,960,000
-
Total reported market value
-
$142,648,487
-
Number of holders
-
15
-
Value change
-
-$3,922,037
-
Number of buys
-
8
-
Number of sells
-
6
Institutional Holders of PTC THERAPEUTICS INC - NOTE 3.000% 8/1 as of Q2 2018
As of 30 Jun 2018,
PTC THERAPEUTICS INC - NOTE 3.000% 8/1 was held by
15 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$143,729,000
in principal (par value) of the bond.
The largest 10 bondholders included
Athyrium Capital Management, LP, CITADEL ADVISORS LLC, Allianz Asset Management GmbH, JANUS HENDERSON GROUP PLC, WOLVERINE ASSET MANAGEMENT LLC, UBS ASSET MANAGEMENT AMERICAS INC, AMERIPRISE FINANCIAL INC, CREDIT SUISSE AG/, OAKTREE CAPITAL MANAGEMENT LP, and Linden Advisors LP.
This page lists
15
institutional bondholders reporting positions
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.